Business Context and Reporting Period
Company: Healthpeak Properties, Inc. (NYSE: DOC)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Healthpeak is a Standard & Poor's 500 company and an umbrella partnership REIT (UPREIT) owning, operating, and developing high-quality healthcare real estate. The portfolio is divided into three reportable segments: Outpatient Medical, Lab, and Senior Housing. The company completed a merger with Physicians Realty Trust on March 1, 2024, significantly expanding its outpatient medical footprint. In December 2025, the company submitted a draft registration statement for the "Janus Living Offering," a proposed IPO of its senior housing portfolio, expected to close in the first half of 2026.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Net Income (Applicable to Common Shares) | $70.5 million | $242.4 million | ($171.9 million) |
| Nareit FFO (Applicable to Common Shares) | $1,269.0 million | $1,092.7 million | $176.3 million |
| FFO as Adjusted | $1,292.3 million | $1,231.9 million | $60.4 million |
| AFFO (Applicable to Common Shares) | $1,183.6 million | $1,140.7 million | $42.9 million |
| Total Revenues | $2,822.5 million | $2,700.4 million | $122.1 million |
| Adjusted NOI (Reportable Segments) | $1,539.9 million | $1,488.4 million | $51.5 million |
| Total Debt (Outstanding) | $9.8 billion | $9.8 billion | — |
| Cash and Cash Equivalents | $467.5 million | $119.8 million | $347.7 million |
| Dividends Declared (Per Share) | $1.22 | $1.20 | $0.02 |
Material Changes vs. Prior Period
- Net Income Decline: Net income applicable to common shares decreased by 71% primarily due to other-than-temporary impairment charges of approximately $176 million on certain unconsolidated lab joint ventures (South San Francisco JVs and Needham Land Parcel JV), a decrease in gains on sales of real estate, and increased interest expense from new debt issuances and assumed merger debt.
- FFO Growth: Nareit FFO increased by 16% driven by higher Adjusted NOI from the outpatient medical and lab segments (due to the 2024 merger and new leasing) and the senior housing segment (due to higher occupancy and resident fees), offsetting the impairment charges which are excluded from FFO.
- Segment Performance:
- Outpatient Medical: Total Portfolio Adjusted NOI increased 7.6% to $795.8 million, driven by the merger and new acquisitions.
- Lab: Total Portfolio Adjusted NOI decreased 3.9% to $567.4 million, primarily due to dispositions and properties in redevelopment, despite a 1.5% increase in Same-Store Adjusted NOI.
- Senior Housing: Total Portfolio Adjusted NOI increased 11.5% to $176.7 million, driven by higher occupancy and resident fees.
- Debt Activity: The company issued $1.0 billion in senior unsecured notes (5.38% due 2035 and 4.75% due 2033) and repaid $800 million in maturing notes. Interest expense increased by $24.7 million.
Guidance, Outlook, and Risks
- Janus Living Offering: The company expects to complete the IPO of Janus Living, Inc. (senior housing portfolio) in the first half of 2026. Healthpeak will retain a majority interest and serve as the external manager. The filing text does not provide specific financial guidance for 2026.
- Dividend Policy: The Board declared a monthly common stock cash dividend of $0.10167 per share for Q1 2026, maintaining the annualized rate of $1.22 per share.
- Key Risks:
- Life Science Sector: Uncertainty regarding NIH funding, regulatory changes, and capital availability for biotech tenants could impact the lab segment's occupancy and rental rates.
- Interest Rates: Elevated interest rates increase borrowing costs and may impact the ability to refinance debt or execute accretive acquisitions.
- Janus Living Execution: Risks related to the timing, terms, and market reception of the Janus Living Offering.
- Regulatory Environment: Changes in healthcare reimbursement (Medicare/Medicaid) and regulations affecting senior housing operators (RIDEA structures) pose operational risks.
Investor Verification Checklist
- Impairment Details: Verify the specific assumptions and valuation models used for the $176 million impairment charge on unconsolidated lab joint ventures to assess the permanence of the value decline.
- Janus Living Terms: Monitor the final terms of the Janus Living Offering, specifically the ownership percentage retained by Healthpeak and the management fee structure, to understand future consolidation and revenue recognition.
- Debt Maturities: Review the debt maturity schedule, noting $995 million in principal payments due in 2026, and assess refinancing risks in the current interest rate environment.
- Lab Occupancy Trends: Track occupancy rates in the lab segment, particularly in South San Francisco, given the reported decline in Same-Store occupancy and the impact of the biotech funding environment.
- Senior Housing Operator Performance: Evaluate the performance of third-party operators in the RIDEA structures, as Healthpeak bears operational risks and liabilities for these properties.